{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:42:35Z","timestamp":1791916955833,"version":"4.3.4"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uveitis consists of a spectrum of inflammatory disorders characterized by ocular inflammation. The underlying pathophysiology consists of a complex interplay of various inflammatory pathways. Interleukin 6 is an important mediator of inflammation in uveitis and constitutes focus of research toward development of newer biological therapies in the management of non-infectious uveitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Pan-blockade of the inflammatory pathways with steroids is generally the first step in the management of acute non-infectious uveitis. However, long-term therapy with steroids is associated with systemic and ocular side effects, thereby necessitating the need for development of steroid sparing agents. IL-6 is a cytokine produced by various immune cells, in response to molecular patterns and affects multiple inflammatory cells. In particular, IL-6 is involved in differentiation of CD-4 cells into Th-17 cells that have been shown to play a significant role in various immune-mediated diseases such as uveitis. This broad-spectrum immunomodulatory activity makes IL-6 an excellent target for immunomodulatory therapy. Tocilizumab was the first IL-6 inhibitor to demonstrate efficacy in humans. It inhibits IL-6 from binding to both membrane-bound and soluble receptor and can be administered via intravenous (IV) and subcutaneous (SC) routes. It has been FDA approved for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Following the approval in systemic diseases, its efficacy was demonstrated in various uveitis studies including a phase 2 clinical trial (STOP-Uveitis). Overall, tocilizumab has shown a good safety profile with the risk of malignancy consistent with that expected in patients with rheumatoid arthritis. However, tocilizumab therapy has been shown to increase the risk for gastrointestinal perforation and dose-dependent neutropenia. Following the success of tocilizumab, several other agents targeting the IL-6 pathway are in the pipeline. These include sirukumab, siltuximab, olokizumab, clazakizumab, and EBI-031 which target IL-6; Sarilumab and ALX-0061 act on the IL-6 receptor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Studies have shown that IL-6 inhibitors can be effective in the management of NIU. In addition, the levels of IL-6 are elevated in other ocular vascular diseases such as retinal vein occlusion and diabetic macular edema. The roles of IL-6 inhibition may be broadened in the future to include the management of retinal vascular diseases and non-uveitic macular edema.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-019-0182-y","type":"journal-article","created":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T20:02:12Z","timestamp":1568577732000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Interleukin-6 inhibition in the management of non-infectious uveitis and beyond"],"prefix":"10.1186","volume":"9","author":[{"given":"Samendra","family":"Karkhur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Hasanreisoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Vigil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sohail","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubbia","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir J.","family":"Sepah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"182_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2017.02.023","volume":"96","author":"J Tode","year":"2017","unstructured":"Tode J et al (2017) Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice. Cytokine 96:8\u201315","journal-title":"Cytokine"},{"key":"182_CR2","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3389\/fimmu.2019.00232","volume":"10","author":"R Horai","year":"2019","unstructured":"Horai R, Caspi RR (2019) Microbiome and autoimmune uveitis. Front Immunol 10:232","journal-title":"Front Immunol"},{"issue":"10","key":"182_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.autrev.2017.08.002","volume":"16","author":"M Mesquida","year":"2017","unstructured":"Mesquida M et al (2017) Targeting interleukin-6 in autoimmune uveitis. Autoimmunity reviews 16(10):1079\u20131089","journal-title":"Autoimmunity reviews"},{"issue":"5","key":"182_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/intimm\/dxq030","volume":"22","author":"T Kishimoto","year":"2010","unstructured":"Kishimoto T (2010) IL-6: from its discovery to clinical applications. International immunology 22(5):347\u2013352","journal-title":"International immunology"},{"issue":"2","key":"182_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cytogfr.2012.09.001","volume":"24","author":"P Ataie-Kachoie","year":"2013","unstructured":"Ataie-Kachoie P et al (2013) Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer. Cytokine & growth factor reviews 24(2):163\u2013173","journal-title":"Cytokine & growth factor reviews"},{"key":"182_CR6","unstructured":"Lin, P. (2015) Targeting interleukin-6 for noninfectious uveitis. Clinical ophthalmology (Auckland, N.Z.) 9, 1697-1702."},{"issue":"3","key":"182_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/092739490500282","volume":"12","author":"VL Perez","year":"2004","unstructured":"Perez VL et al (2004) Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocular immunology and inflammation 12(3):193\u2013201","journal-title":"Ocular immunology and inflammation"},{"issue":"11","key":"182_CR8","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1007\/s00417-013-2436-y","volume":"251","author":"A Adan","year":"2013","unstructured":"Adan A et al (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 251(11):2627\u20132632","journal-title":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"issue":"7","key":"182_CR9","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1097\/IAE.0000000000001690","volume":"38","author":"Marina Mesquida","year":"2018","unstructured":"Mesquida, M. et al. (2018) Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina (Philadelphia, Pa.) 38 (7), 1361-1370.","journal-title":"Retina"},{"issue":"12","key":"182_CR10","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","volume":"121","author":"M Mesquida","year":"2014","unstructured":"Mesquida M et al (2014) Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology 121(12):2380\u20132386","journal-title":"Ophthalmology"},{"key":"182_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","volume":"183","author":"YJ Sepah","year":"2017","unstructured":"Sepah YJ et al (2017) Primary (Month-6) outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. American Journal of Ophthalmology 183:71\u201380","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"182_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/intimm\/dxu081","volume":"27","author":"S Kang","year":"2015","unstructured":"Kang S et al (2015) Therapeutic uses of anti-interleukin-6 receptor antibody. International immunology 27(1):21\u201329","journal-title":"International immunology"},{"issue":"12","key":"182_CR13","first-page":"720","volume":"10","author":"LH Calabrese","year":"2014","unstructured":"Calabrese LH, Rose-John S (2014) IL-6 biology: implications for clinical targeting in rheumatic disease. Nature reviews. Rheumatology 10(12):720\u2013727","journal-title":"Rheumatology"},{"issue":"2","key":"182_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1201044","volume":"190","author":"Judith Hoge","year":"2012","unstructured":"Hoge, J. et al. (2013) IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. Journal of immunology (Baltimore, Md.: 1950) 190 (2), 703-711.","journal-title":"The Journal of Immunology"},{"issue":"5566","key":"182_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1071059","volume":"296","author":"P. Matzinger","year":"2002","unstructured":"Matzinger, P. (2002) The danger model: a renewed sense of self. Science (New York, N.Y.) 296 (5566), 301-305.","journal-title":"Science"},{"issue":"1","key":"182_CR16","doi-asserted-by":"publisher","first-page":"e000213-2015-00","DOI":"10.1136\/rmdopen-2015-000213","volume":"2","author":"A Rubbert-Roth","year":"2016","unstructured":"Rubbert-Roth A et al (2016) Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD open 2(1):e000213-2015-000213 eCollection 2016","journal-title":"RMD open"},{"issue":"12","key":"182_CR17","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1373\/clinchem.2011.169839","volume":"57","author":"S Devaraj","year":"2011","unstructured":"Devaraj S et al (2011) C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clinical chemistry 57(12):1757\u20131761","journal-title":"Clinical chemistry"},{"issue":"3","key":"182_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1042\/bj3340489","volume":"334","author":"Liselotte E. JENSEN","year":"1998","unstructured":"Jensen, L.E. and Whitehead, A.S. (1998) Regulation of serum amyloid A protein expression during the acute-phase response. The Biochemical journal 334 ( Pt 3) (Pt 3), 489-503.","journal-title":"Biochemical Journal"},{"issue":"5704","key":"182_CR19","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E. Nemeth","year":"2004","unstructured":"Nemeth, E. et al. (2004) Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (New York, N.Y.) 306 (5704), 2090-2093.","journal-title":"Science"},{"issue":"15","key":"182_CR20","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1073\/pnas.86.15.5953","volume":"86","author":"T Ishibashi","year":"1989","unstructured":"Ishibashi T et al (1989) Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proceedings of the National Academy of Sciences of the United States of America 86(15):5953\u20135957","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"182_CR21","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","volume":"47","author":"M Hashizume","year":"2008","unstructured":"Hashizume M et al (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford, England) 47(11):1635\u20131640","journal-title":"Rheumatology (Oxford, England)"},{"issue":"6","key":"182_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.11143","volume":"48","author":"H Nakahara","year":"2003","unstructured":"Nakahara H et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis and Rheumatism 48(6):1521\u20131529","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"182_CR23","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.1167\/iovs.12-9861","volume":"53","author":"EF Gillespie","year":"2012","unstructured":"Gillespie EF et al (2012) Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-kappaB. Investigative ophthalmology & visual science 53(12):7746\u20137753","journal-title":"Investigative ophthalmology & visual science"},{"issue":"10","key":"182_CR24","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood.V99.10.3756","volume":"99","author":"AT Brenne","year":"2002","unstructured":"Brenne AT et al (2002) Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99(10):3756\u20133762","journal-title":"Blood"},{"issue":"Pt 1","key":"182_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj20030407","volume":"374","author":"PC Heinrich","year":"2003","unstructured":"Heinrich PC et al (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. The Biochemical journal 374(Pt 1):1\u201320","journal-title":"The Biochemical journal"},{"key":"182_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","volume":"15","author":"T Taga","year":"1997","unstructured":"Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annual Review of Immunology 15:797\u2013819","journal-title":"Annual Review of Immunology"},{"issue":"9","key":"182_CR27","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. International journal of biological sciences 8(9):1237\u20131247","journal-title":"International journal of biological sciences"},{"key":"182_CR28","first-page":"2123","volume":"15","author":"GJ Seong","year":"2009","unstructured":"Seong GJ et al (2009) TGF-beta-induced interleukin-6 participates in transdifferentiation of human Tenon's fibroblasts to myofibroblasts. Molecular vision 15:2123\u20132128","journal-title":"Molecular vision"},{"issue":"3","key":"182_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10384-011-0002-x","volume":"55","author":"S Sugaya","year":"2011","unstructured":"Sugaya S et al (2011) Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Japanese journal of ophthalmology 55(3):277\u2013282","journal-title":"Japanese journal of ophthalmology"},{"issue":"23","key":"182_CR30","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","volume":"585","author":"T Tanaka","year":"2011","unstructured":"Tanaka T et al (2011) Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS letters 585(23):3699\u20133709","journal-title":"FEBS letters"},{"issue":"202","key":"182_CR31","doi-asserted-by":"publisher","first-page":"ra85","DOI":"10.1126\/scisignal.2001637","volume":"4","author":"T Tanaka","year":"2011","unstructured":"Tanaka T et al (2011) PDLIM2 inhibits T helper 17 cell development and granulomatous inflammation through degradation of STAT3. Science signaling 4(202):ra85","journal-title":"Science signaling"},{"issue":"4","key":"182_CR32","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","volume":"82","author":"M Narazaki","year":"1993","unstructured":"Narazaki M et al (1993) Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 82(4):1120\u20131126","journal-title":"Blood"},{"issue":"17","key":"182_CR33","doi-asserted-by":"publisher","first-page":"12848","DOI":"10.1074\/jbc.275.17.12848","volume":"275","author":"J Schmitz","year":"2000","unstructured":"Schmitz J et al (2000) SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. The Journal of biological chemistry 275(17):12848\u201312856","journal-title":"The Journal of biological chemistry"},{"issue":"4","key":"182_CR34","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","volume":"86","author":"T Kishimoto","year":"1995","unstructured":"Kishimoto T et al (1995) Interleukin-6 family of cytokines and gp130. Blood 86(4):1243\u20131254","journal-title":"Blood"},{"issue":"5","key":"182_CR35","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","volume":"1813","author":"J Scheller","year":"2011","unstructured":"Scheller J et al (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et biophysica acta 1813(5):878\u2013888","journal-title":"Biochimica et biophysica acta"},{"key":"182_CR36","doi-asserted-by":"crossref","unstructured":"Genovese, M.C. et al. (2015) Sarilumab Plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis & rheumatology (Hoboken, N.J.) 67 (6), 1424-1437.","DOI":"10.1002\/art.39093"},{"issue":"9","key":"182_CR37","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS et al (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases 73(9):1616\u20131625","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"182_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","volume":"19","author":"G Jego","year":"2003","unstructured":"Jego G et al (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19(2):225\u2013234","journal-title":"Immunity"},{"issue":"8","key":"182_CR39","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/icb.2012.17","volume":"90","author":"SA Diehl","year":"2012","unstructured":"Diehl SA et al (2012) IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunology and cell biology 90(8):802\u2013811","journal-title":"Immunology and cell biology"},{"issue":"1","key":"182_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clim.2008.08.018","volume":"130","author":"Oliver Dienz","year":"2009","unstructured":"Dienz, O. and Rincon, M. (2009) The effects of IL-6 on CD4 T cell responses. Clinical immunology (Orlando, Fla.) 130 (1), 27-33.","journal-title":"Clinical Immunology"},{"issue":"9","key":"182_CR41","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N et al (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proceedings of the National Academy of Sciences of the United States of America 108(9):3701\u20133706","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6159","key":"182_CR42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/332083a0","volume":"332","author":"M Kawano","year":"1988","unstructured":"Kawano M et al (1988) Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas. Nature 332(6159):83\u201385","journal-title":"Nature"},{"issue":"5","key":"182_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/75068","volume":"6","author":"R Atreya","year":"2000","unstructured":"Atreya R et al (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature medicine 6(5):583\u2013588","journal-title":"Nature medicine"},{"key":"182_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T et al (2009) IL-17 and Th17 Cells. Annual Review of Immunology 27:485\u2013517","journal-title":"Annual Review of Immunology"},{"issue":"7090","key":"182_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235\u2013238","journal-title":"Nature"},{"issue":"7","key":"182_CR46","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. European journal of immunology 40(7):1830\u20131835","journal-title":"European journal of immunology"},{"issue":"3","key":"182_CR47","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.4049\/jimmunol.0802923","volume":"183","author":"Wendy A. Neveu","year":"2009","unstructured":"Neveu, W.A. et al. (2009) IL-6 is required for airway mucus production induced by inhaled fungal allergens. Journal of immunology (Baltimore, Md.: 1950) 183 (3), 1732-1738.","journal-title":"The Journal of Immunology"},{"issue":"6","key":"182_CR48","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1074-7613(00)00078-9","volume":"13","author":"S Diehl","year":"2000","unstructured":"Diehl S et al (2000) Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13(6):805\u2013815","journal-title":"Immunity"},{"issue":"3","key":"182_CR49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM et al (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis and Rheumatism 63(3):609\u2013621","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"182_CR50","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P et al (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases 67(11):1516\u20131523","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"182_CR51","first-page":"129-018-1614-z","volume":"20","author":"V Strand","year":"2018","unstructured":"Strand V et al (2018) Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis research & therapy 20(1):129-018-1614-z","journal-title":"Arthritis research & therapy"},{"issue":"1","key":"182_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Annals of the Rheumatic Diseases 69(1):88\u201396","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"182_CR53","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/rheumatology\/kex443","volume":"57","author":"E Choy","year":"2018","unstructured":"Choy E et al (2018) Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford, England) 57(3):499\u2013507","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"182_CR54","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1073\/pnas.84.1.228","volume":"84","author":"T Hirano","year":"1987","unstructured":"Hirano T et al (1987) Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proceedings of the National Academy of Sciences of the United States of America 84(1):228\u2013231","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"182_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/030097402320318387","volume":"31","author":"K Hamzaoui","year":"2002","unstructured":"Hamzaoui K et al (2002) Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol 31(4):205\u2013210","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"182_CR56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cei.12295","volume":"176","author":"M Mesquida","year":"2014","unstructured":"Mesquida M et al (2014) Interleukin-6 blockade in ocular inflammatory diseases. Clinical and experimental immunology 176(3):301\u2013309","journal-title":"Clinical and experimental immunology"},{"issue":"1","key":"182_CR57","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1084\/jem.169.1.333","volume":"169","author":"A Waage","year":"1989","unstructured":"Waage A et al (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. The Journal of experimental medicine 169(1):333\u2013338","journal-title":"The Journal of experimental medicine"},{"issue":"4","key":"182_CR58","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","volume":"48","author":"T Yoshimura","year":"2009","unstructured":"Yoshimura T et al (2009) Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford, England) 48(4):347\u2013354","journal-title":"Rheumatology (Oxford, England)"},{"issue":"6","key":"182_CR59","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1167\/iovs.10-6272","volume":"52","author":"H Haruta","year":"2011","unstructured":"Haruta H et al (2011) Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Investigative ophthalmology & visual science 52(6):3264\u20133271","journal-title":"Investigative ophthalmology & visual science"},{"issue":"3","key":"182_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pathophys.2017.05.005","volume":"24","author":"F Zahir-Jouzdani","year":"2017","unstructured":"Zahir-Jouzdani F et al (2017) Interleukin-6 participation in pathology of ocular diseases. Pathophysiology 24(3):123\u2013131","journal-title":"Pathophysiology"},{"issue":"5","key":"182_CR61","first-page":"917","volume":"31","author":"PI Murray","year":"1990","unstructured":"Murray PI et al (1990) Aqueous humor interleukin-6 levels in uveitis. Investigative ophthalmology & visual science 31(5):917\u2013920","journal-title":"Investigative ophthalmology & visual science"},{"issue":"Suppl","key":"182_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/02713689208999530","volume":"11","author":"JH de Boer","year":"1992","unstructured":"de Boer JH et al (1992) Analysis of IL-6 levels in human vitreous fluid obtained from uveitis patients, patients with proliferative intraocular disorders and eye bank eyes. Current eye research 11(Suppl):181\u2013186","journal-title":"Current eye research"},{"issue":"7-8","key":"182_CR63","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/02713680701523147","volume":"32","author":"M Kramer","year":"2007","unstructured":"Kramer M et al (2007) Serum cytokine levels in active uveitis and remission. Current eye research 32(7-8):669\u2013675","journal-title":"Current eye research"},{"key":"182_CR64","doi-asserted-by":"crossref","unstructured":"Kishimoto, T. and Ishizaka, K. (1974) Regulation of antibody response in vitro. 8. Multiplicity of soluble factors released from carrier-specific cells. Journal of immunology (Baltimore, Md.: 1950) 112 (5), 1685-1697.","DOI":"10.4049\/jimmunol.112.5.1685"},{"issue":"9","key":"182_CR65","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","volume":"110","author":"H Funatsu","year":"2003","unstructured":"Funatsu H et al (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110(9):1690\u20131696","journal-title":"Ophthalmology"},{"issue":"1","key":"182_CR66","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ophtha.2008.09.034","volume":"116","author":"H Noma","year":"2009","unstructured":"Noma H et al (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116(1):87\u201393","journal-title":"Ophthalmology"},{"issue":"3","key":"182_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10384-011-0004-8","volume":"55","author":"Y Suzuki","year":"2011","unstructured":"Suzuki Y et al (2011) Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 55(3):256\u2013263","journal-title":"Jpn J Ophthalmol"},{"key":"182_CR68","first-page":"1325","volume":"6","author":"A Sadaka","year":"2012","unstructured":"Sadaka A, Giuliari GP (2012) Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol 6:1325\u20131333","journal-title":"Clin Ophthalmol"},{"key":"182_CR69","doi-asserted-by":"crossref","first-page":"U308","DOI":"10.1167\/iovs.04-0015","volume":"45","author":"AA Leonardi","year":"2004","unstructured":"Leonardi AA et al (2004) Multiple cytokine evaluation in tears of allergic conjunctivitis patients by Multi-Cytokine Bead Assay. Investigative Ophthalmology & Visual Science 45:U308\u2013U308","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"182_CR70","first-page":"2400","volume":"17","author":"A Higuchi","year":"2011","unstructured":"Higuchi A et al (2011) IL-6 induction in desiccated corneal epithelium in vitro and in vivo. Mol Vis 17:2400\u20132406","journal-title":"Mol Vis"},{"issue":"7","key":"182_CR71","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.ophtha.2012.01.031","volume":"119","author":"NA Carnt","year":"2012","unstructured":"Carnt NA et al (2012) Association of single nucleotide polymorphisms of interleukins-1beta, -6, and -12B with contact lens keratitis susceptibility and severity. Ophthalmology 119(7):1320\u20131327","journal-title":"Ophthalmology"},{"issue":"3","key":"182_CR72","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1167\/iovs.09-3375","volume":"51","author":"M Rojas","year":"2010","unstructured":"Rojas M et al (2010) Role of IL-6 in angiotensin II-induced retinal vascular inflammation. Invest Ophthalmol Vis Sci 51(3):1709\u20131718","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"182_CR73","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.mehy.2012.12.042","volume":"80","author":"AC Lewis","year":"2013","unstructured":"Lewis AC (2013) Interleukin-6 in the pathogenesis of posterior capsule opacification and the potential role for interleukin-6 inhibition in the future of cataract surgery. Med Hypotheses 80(4):466\u2013474","journal-title":"Med Hypotheses"},{"issue":"1","key":"182_CR74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.V79.1.45.45","volume":"79","author":"A Tobler","year":"1992","unstructured":"Tobler A et al (1992) Glucocorticoids downregulate gene expression of GM-CSF, NAP-1\/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood 79(1):45\u201351","journal-title":"Blood"},{"issue":"3","key":"182_CR75","doi-asserted-by":"publisher","first-page":"C539","DOI":"10.1152\/ajpcell.00047.2010","volume":"299","author":"MO Griffin","year":"2010","unstructured":"Griffin MO et al (2010) Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. American journal of physiology. Cell physiology 299(3):C539\u2013C548","journal-title":"American journal of physiology. Cell physiology"},{"issue":"2","key":"182_CR76","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"AN Sapadin","year":"2006","unstructured":"Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. Journal of the American Academy of Dermatology 54(2):258\u2013265","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"182_CR77","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.phrs.2011.05.011","volume":"64","author":"Y Gu","year":"2011","unstructured":"Gu Y et al (2011) Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase. Pharmacological research 64(6):595\u2013601","journal-title":"Pharmacological research"},{"issue":"6","key":"182_CR78","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/1759720X12455960","volume":"4","author":"S Yokota","year":"2012","unstructured":"Yokota S et al (2012) Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Therapeutic advances in musculoskeletal disease 4(6):387\u2013397","journal-title":"Therapeutic advances in musculoskeletal disease"},{"issue":"2","key":"182_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X et al (2014) Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacology & therapeutics 141(2):125\u2013139","journal-title":"Pharmacology & therapeutics"},{"issue":"10042","key":"182_CR80","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","volume":"388","author":"JWJ Bijlsma","year":"2016","unstructured":"Bijlsma JWJ et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet (London, England) 388(10042):343\u2013355","journal-title":"Lancet (London, England)"},{"issue":"6","key":"182_CR81","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/annrheumdis-2015-207628","volume":"75","author":"GR Burmester","year":"2016","unstructured":"Burmester GR et al (2016) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the Rheumatic Diseases 75(6):1081\u20131091","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9877","key":"182_CR82","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","volume":"381","author":"C Gabay","year":"2013","unstructured":"Gabay C et al (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (London, England) 381(9877):1541\u20131550","journal-title":"Lancet (London, England)"},{"issue":"5","key":"182_CR83","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/09273948.2011.606593","volume":"19","author":"A Muselier","year":"2011","unstructured":"Muselier A et al (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm 19(5):382\u2013383","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"182_CR84","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","volume":"22","author":"T Hirano","year":"2012","unstructured":"Hirano T et al (2012) A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Modern rheumatology 22(2):298\u2013302","journal-title":"Modern rheumatology"},{"issue":"6","key":"182_CR85","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.3899\/jrheum.120010","volume":"39","author":"C Tappeiner","year":"2012","unstructured":"Tappeiner C et al (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? The Journal of rheumatology 39(6):1294\u20131295","journal-title":"The Journal of rheumatology"},{"issue":"4 Suppl 84","key":"182_CR86","first-page":"S75","volume":"32","author":"M Papo","year":"2014","unstructured":"Papo M et al (2014) Tocilizumab in severe and refractory non-infectious uveitis. Clinical and experimental rheumatology 32(4 Suppl 84):S75\u2013S79","journal-title":"Clinical and experimental rheumatology"},{"issue":"1","key":"182_CR87","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"GR Burmester","year":"2014","unstructured":"Burmester GR et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Annals of the Rheumatic Diseases 73(1):69\u201374","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"182_CR88","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/acr.22384","volume":"66","author":"A Kivitz","year":"2014","unstructured":"Kivitz A et al (2014) Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis care & research 66(11):1653\u20131661","journal-title":"Arthritis care & research"},{"issue":"3","key":"182_CR89","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"A Ogata","year":"2014","unstructured":"Ogata A et al (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis care & research 66(3):344\u2013354","journal-title":"Arthritis care & research"},{"issue":"4","key":"182_CR90","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/jcph.826","volume":"57","author":"H Abdallah","year":"2017","unstructured":"Abdallah H et al (2017) Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. Journal of clinical pharmacology 57(4):459\u2013468","journal-title":"Journal of clinical pharmacology"},{"issue":"3","key":"182_CR91","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld A et al (2017) Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Annals of the Rheumatic Diseases 76(3):504\u2013510","journal-title":"Annals of the Rheumatic Diseases"},{"key":"182_CR92","doi-asserted-by":"crossref","unstructured":"Xie, F. et al. (2016) Brief Report: risk of gastrointestinal perforation among rheumatoid Arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis & rheumatology (Hoboken, N.J.) 68 (11), 2612-2617.","DOI":"10.1002\/art.39761"},{"issue":"2","key":"182_CR93","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40744-016-0037-z","volume":"3","author":"S Monemi","year":"2016","unstructured":"Monemi S et al (2016) Incidence of Gastrointestinal perforations in patients with Rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources. Rheumatology and therapy 3(2):337\u2013352","journal-title":"Rheumatology and therapy"},{"issue":"9","key":"182_CR94","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis and Rheumatism 56(9):2886\u20132895","journal-title":"Arthritis and Rheumatism"},{"issue":"25","key":"182_CR95","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F et al (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. The New England journal of medicine 367(25):2385\u20132395","journal-title":"The New England journal of medicine"},{"issue":"6","key":"182_CR96","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3899\/jrheum.150457","volume":"44","author":"F Espinoza","year":"2017","unstructured":"Espinoza F et al (2017) Biologic Disease-modifying antirheumatic drug (bDMARD)-induced neutropenia: a registry from a retrospective cohort of patients with rheumatic diseases treated with 3 classes of intravenous bDMARD. The Journal of rheumatology 44(6):844\u2013849","journal-title":"The Journal of rheumatology"},{"issue":"4","key":"182_CR97","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3899\/jrheum.130690","volume":"41","author":"S Yokota","year":"2014","unstructured":"Yokota S et al (2014) Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. The Journal of rheumatology 41(4):759\u2013767","journal-title":"The Journal of rheumatology"},{"issue":"9","key":"182_CR98","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2015-207818","volume":"75","author":"S Yokota","year":"2016","unstructured":"Yokota S et al (2016) Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Annals of the Rheumatic Diseases 75(9):1654\u20131660","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"182_CR99","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","volume":"126","author":"J Heissigerova","year":"2019","unstructured":"Heissigerova J et al (2019) Efficacy and Safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology 126(3):428\u2013437","journal-title":"Ophthalmology"},{"issue":"12","key":"182_CR100","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1136\/annrheumdis-2017-211328","volume":"76","author":"T Takeuchi","year":"2017","unstructured":"Takeuchi T et al (2017) Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Annals of the Rheumatic Diseases 76(12):2001\u20132008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"13","key":"182_CR101","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","volume":"19","author":"R Kurzrock","year":"2013","unstructured":"Kurzrock R et al (2013) A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical cancer research : an official journal of the American Association for Cancer Research 19(13):3659\u20133670","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"9","key":"182_CR102","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1136\/annrheumdis-2013-204760","volume":"73","author":"MC Genovese","year":"2014","unstructured":"Genovese MC et al (2014) Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Annals of the Rheumatic Diseases 73(9):1607\u20131615","journal-title":"Annals of the Rheumatic Diseases"},{"key":"182_CR103","doi-asserted-by":"crossref","unstructured":"Weinblatt, M.E. et al. (2015) The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo\/active-controlled, dose-ranging study. Arthritis & rheumatology (Hoboken, N.J.) 67 (10), 2591-2600.","DOI":"10.1002\/art.39249"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-019-0182-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12348-019-0182-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-019-0182-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T08:55:24Z","timestamp":1721724924000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-019-0182-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1186\/s12348-019-0182-y","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"4 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}